Biophytis (BPTSY) wins Brazil funding for obesity phase 2 trial

Rhea-AI Filing Summary

Biophytis S.A. filed a Form 6-K to share a press release dated September 15, 2025. The company reports it has secured public funding in Brazil for an obesity phase 2 trial and has signed agreements with leading local clinical partners to conduct this study.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: September 15, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On September 15, 2025, Biophytis S.A. issued a press release announcing that the company secures public funding in Brazil for obesity phase 2 prial and signs agreements with leading local clinical partners. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated September 15, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: September 15, 2025	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer

FAQ

What did Biophytis (BPTSY) announce in its latest 6-K filing?

Biophytis announced it secured public funding in Brazil for an obesity phase 2 trial and signed agreements with leading local clinical partners. This information comes from a press release dated September 15, 2025, attached as an exhibit to the Form 6-K.

What is the purpose of the public funding Biophytis (BPTSY) obtained in Brazil?

The public funding secured in Brazil is intended to support Biophytis’s obesity phase 2 clinical trial. According to the filing, this funding will back the study’s execution alongside agreements with leading local clinical partners involved in running the trial.

Which clinical stage program is mentioned in Biophytis (BPTSY) 6-K filing?

The filing mentions an obesity phase 2 trial. Biophytis states in the attached press release that it has secured public funding in Brazil for this phase 2 clinical study and has signed agreements with leading local partners to help conduct the trial.

What partnerships did Biophytis (BPTSY) report in Brazil?

Biophytis reported signing agreements with leading local clinical partners in Brazil. These partners are expected to support the company’s obesity phase 2 trial, as described in the press release attached to the Form 6-K dated September 15, 2025.

When was the Biophytis (BPTSY) press release about Brazil obesity funding issued?

The press release was issued on September 15, 2025. Biophytis attached this press release as Exhibit 99.1 to its Form 6-K, detailing public funding in Brazil for an obesity phase 2 trial and agreements with leading local clinical partners.

Where can investors find full details of Biophytis (BPTSY) Brazil funding news?

Full details are contained in the press release attached as Exhibit 99.1 to the Form 6-K. The filing states that this document describes the public funding in Brazil for the obesity phase 2 trial and the related local clinical partnerships.